

Medical Policies



Policy Number: fep_8.01.67

Policy Name: Medical Management of Obstructive Sleep Apnea Syndrome

Policy Type: Medical

Policy Subtype: Pulmonary Disease

Effective Date: 10-01-2026

Review Date: 09-01-2027

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Annual Effective Policy Date: October 1, 2026

Original Policy Date: September 2022

Related Policies:

7.01.101 - Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Medical Management Of Obstructive Sleep Apnea Syndrome

DESCRIPTION

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. Conventional medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of continuous positive airway pressure (CPAP) during sleep. Novel treatments include nasal expiratory positive airway pressure (EPAP) and oral pressure therapy.

OBJECTIVE

The objective of this evidence review is to evaluate the evidence for established and novel methods of treating obstructive sleep apnea.

POLICY STATEMENT

Medical Management Of Obstructive Sleep Apnea Syndrome

Auto-adjusting positive airway pressure (APAP) may be considered **medically necessary** for the titration of pressure in individuals with clinically significant obstructive sleep apnea (OSA) defined as those who have at least one of the following:

- An Apnea/Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), or Respiratory Event Index (REI) of at least 15 events per hour, OR
- An AHI, RDI, or REI of at least 5 events per hour in an individual with 1 or more signs or symptoms associated with OSA (eg, excessive daytime sleepiness, hypertension, cardiovascular heart disease, or stroke); OR
- If there is a significant change in weight or change in symptoms suggesting that continuous positive airway pressure (CPAP) should be retitrated or discontinued.

CPAP may be considered **medically necessary** in adult individuals with clinically significant OSA defined as any of the following:

- An AHI, RDI, or REI ≥ 15 events per hour, OR
- An AHI, RDI, or REI ≥ 5 events per hour in an individual with 1 or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular heart disease, or stroke).

CPAP may be considered **medically necessary** in pediatric individuals with clinically significant OSA defined as any of the following:

- An AHI or RDI ≥ 5 events per hour OR
- An AHI or RDI ≥ 1.5 events per hour in an individual with excessive daytime sleepiness, behavioral problems or hyperactivity.

Bilevel positive airway pressure (PAP) or APAP may be considered **medically necessary** in individuals with clinically significant OSA who meet one of the following criteria:

- have failed a prior trial of CPAP or
- for whom bilevel PAP is found to be more effective in the sleep lab.

Intraoral appliances (tongue-retaining devices or mandibular advancing/positioning devices) may be considered **medically necessary** in adults with clinically significant OSA who meet all of the following conditions:

- OSA as defined by having one of the following:
 - An AHI, RDI, or REI ≥ 15 events per hour, OR
 - An AHI, RDI, or REI ≥ 5 events per hour in an individual with 1 or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular heart disease, or stroke).
- A trial with CPAP has failed or is contraindicated, AND
- The device is prescribed by a treating physician, AND
- The device is custom-fitted by qualified dental personnel, AND
- There is absence of temporomandibular dysfunction or periodontal disease.

The use of CPAP, bi-level PAP, APAP, and intraoral appliances that do not meet the above criteria is considered **investigational** for the treatment of OSA.

The use of an abbreviated daytime sleep session for acclimation to CPAP (PAP-NAP) is considered **investigational**.

The use of a sleep positioning trainer with vibration is considered **investigational** for the treatment of positional OSA.

The use of neuromuscular electrical tongue stimulation is considered **investigational** for the treatment of OSA.

Palate and mandible expansion devices are considered **investigational** for the treatment of OSA.

Nasal expiratory positive airway pressure (EPAP) and oral pressure therapy devices are considered **investigational**.

Procedure Codes:

0964T	0965T	0966T	A7027	A7028	A7029	A7034	A7035	A7036
A7037	A7038	A7039	A7049	E0470	E0471	E0485	E0486	E0490
E0491	E0492	E0493	E0530	E0561	E0562	E0601	K1027	

POLICY GUIDELINES

Specialist Training

Treatment of individuals diagnosed with obstructive sleep apnea (OSA) should be initiated and monitored by a professional trained in sleep medicine. It is important to monitor symptoms and adherence to positive airway pressure (PAP) treatment (e.g., review of symptoms and device utilization at 90 days with a minimum of 4 hours per night for at least 5 nights per week).

Risk Factors For Obstructive Sleep Apnea

Although not an exclusive list, individuals with all of the following symptoms are considered to be at high risk for OSA:

- habitual snoring;
- observed apneas;
- excessive daytime sleepiness;
- a body mass index (BMI) greater than 35 kg/m².

If no bed partner is available to report snoring or observed apneas, other signs and symptoms suggestive of OSA (e.g., age of the individuals, male gender, thick neck, craniofacial or upper airway soft tissue abnormalities, unexplained hypertension) may be considered. Objective clinical prediction rules are being developed; at present, risk assessment is based primarily on clinical judgment.

The STOP-BANG questionnaire, a method developed for nonsleep specialists, assesses the signs and symptoms of OSA (Snore, Tired, Observed apnea, blood Pressure, BMI, Age, Neck, Gender), and has been shown to have 97% sensitivity and 96% negative predictive value (specificity, 33%) for the identification of individuals with severe OSA (Apnea/Hypopnea Index [AHI] >30 events per hour). Overnight oximetry has been used by some sleep specialists as a component of the risk assessment but is inadequate for the diagnosis of OSA. Therefore, a follow-up polysomnography (PSG) or home sleep apnea test would still be required to confirm or exclude a diagnosis of OSA.

Obstructive Sleep Apnea In Children

The presentation of OSA in children may differ from that of adults. In addition, the first-line treatment in children is usually adenotonsillectomy. Continuous positive airway pressure (CPAP) is an option for children who are not candidates for surgery or who have an inadequate response to surgery.

Significant Weight Change

There is no established threshold for significant change in weight. Studies have reported improvements in OSA with an average weight loss of 20 kg or 20% of body weight.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Weight Loss Programs

Weight loss is frequently recommended for obese individuals with obstructive sleep apnea (OSA). Plans may want to review their policies on weight loss programs in general and determine whether such policies should apply to individuals with OSA. In some instances, continuous positive airway pressure (CPAP) may also be recommended while the individual is in a weight loss program; if the weight loss program is successful, further therapy may be unnecessary. If the weight loss program is unsuccessful, and the individual does not tolerate CPAP (or auto-adjusting positive airway pressure or bilevel positive airway pressure), surgical therapy may be considered.

Management of OSA with GLP-1/GIP receptor agonists is not evaluated in this medical policy.

FDA REGULATORY STATUS

A variety of oral appliances have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for the treatment of snoring and mild-to-moderate OSA, including the Narval™ CC, Lamberg Sleep Well Smarttrusion, 1st Snoring Appliance, Full Breath Sleep Appliance, PM Positioner, Snorenti, Snorex, Osap, DeSRA, Elastomeric Sleep Appliance, Snoremaster Snore Remedy, Snore-no-More, Napa, Snoar™ Open Airway Appliance, and The Equalizer Airway Device.

FDA product code: LQZ.

Various PAP devices have been cleared by the FDA through the 510(k) process since 1977. Bilevel PAP devices were first cleared for marketing in 1996.

FDA product codes: BZD, MNT.

In December 2024, the FDA approved Zepbound (tirzepatide), a once-weekly GLP-1/GIP receptor agonist, as a treatment option for moderate-to-severe OSA in combination with exercise and a reduced-calorie diet.

Novel devices for OSA diagnosis and treatment are described in Table 1.

Table 1. Novel Devices For OSA Diagnosis And Treatment

Device	Manufacturer	Description	510(K) Number	FDA Product Code	Year
<i>Diagnosis</i>					
Accusom	Novasom, Inc	The ACCUSOM device is a battery and line-powered ventilatory effort recorder. The ACCUSOM device is indicated for use in the diagnostic evaluation of adults with possible sleep apnea.	K110486	MNR	2011
SOMNOtouch RESP	Somnomedics, GMBH	The SOMNOtouch RESP is a portable physiological signal recorder. It is indicated for use in the recording, displaying, monitoring, printing, and storage of biophysical parameters for the purpose of assisting in the diagnosis of sleep disorders and sleep related respiratory disorders of adult patients.	K140861	MNR	2015
SleepImage System	MyCardio	Software as a medical device that provides automated analysis of sleep data from a single photoplethysmogram sensor to aid in the evaluation of sleep disorders.	K163696	MNR	2017
ZMachine synergy	Consolidated Research of Richmond, Inc	The Zmachine Synergy is an EEG and respiratory signal recorder. The device is intended for use by adult patients in the home or clinical environment, under the direction of a qualified healthcare practitioner, to aid in the diagnosis of sleep disorders.	K172986	OLV, OMC, MNR	2017
ApneaTrak	Cadwell Industries, Inc	The Cadwell ApneaTrak device is intended for home sleep testing, including the acquisition of physiological and environmental data. The recorded signals are then transmitted to a PC so that they can be viewed. ApneaTrak is intended for use on patients older than 2 years of age.	K192624	MNR	2020
Belun ring	Belun Technology Company Limited	The Belun Sleep System BLS-100 is a wearable device intended to record, analyze, display, export, and store biophysical parameters to aid in evaluating moderate to severe sleep-related breathing disorders of adult patients suspected of sleep apnea.	K211407	MNR	2021
ANNE Sleep	Sibel, Inc.	ANNE Sleep is a wearable sensor system intended for use in the collection, analysis, display, and storage of physiological parameters to aid in the evaluation of sleep-related breathing disorders of adult patients suspected of sleep apnea.	K220095	MNR	2022
BresoDX1	Bresotec Inc	BresoDX1 is indicated for use as an aid in the diagnosis of moderate to severe sleep apnea in adult patients. BresDX1 records a patient's physiological signals during sleep and scores apneas and hypopneas.	K220012	MNR	2022
Cerebra Sleep System	Cerebra Medical, Ltd	The Cerebra Sleep System is an integrated diagnostic platform that acquires, transmits, analyzes, and displays physiological signals from adult patients, and then provides for scoring (automatic and manual), editing, and generating reports. The system uses polysomnography (PSG) to record the electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), accelerometry, acoustic signals, nasal airflow, thoracic and abdomen respiratory effort, pulse rate, and oxyhemoglobin saturation, depending on the sleep study configuration.	K213007	OLV	2022
NightOwl	Ectosense Nv	The NightOwl is a wearable device intended for use in the recording, analysis, displaying, exporting, and storage of biophysical parameters to aid in the evaluation of sleep-related breathing disorders of adult patients suspected of sleep apnea.	K220028	MNR	2022
Sunrise	Sunrise SA	The Sunrise device is a non-invasive home care aid in the evaluation of OSA in patients 18 years and older with suspicions of sleep breathing disorders.	K222262	MNR	2022

WatchPAT	Itamar Medical, Ltd	The WatchPAT ONE (WP1) device is a noninvasive home care device for use with patients suspected to have sleep related breathing disorders. The WP1 is a diagnostic aid for the detection of sleep related breathing disorders, sleep staging (Rapid Eye Movement (REM) Sleep, Light Sleep, Deep Sleep and Wake), snoring level and body position.	K223675	MNR	2022
AcuPebble OX100	Acurable Limited	AcuPebble Ox100 is a wearable device intended for use in the recording, analysis, displaying, exporting, and storage of biophysical parameters to aid in the evaluation of adult patients with, or with suspected, OSA	K222950	MNR	2023
Onera STS	Onera B.V	Onera STS measures and records multiple physiological parameters from a patient during a sleep study which are used by clinicians to make a decision on the diagnosis of sleep disorders.	K223573	MNR	2023
Wesper Lab	Wesper, Inc	The Wesper Lab is a digital recording device designed to be used under the direction of a physician or trained technician but may be applied by a layperson. Wesper Lab records multiple physiological parameters from a sleeping patient for the purpose of simultaneous or subsequent display of the parameters. The displayed data assists in the identification of sleep apnea by trained personnel.	K221816	MNR	2023
Withings Sleep Rx	Withings	The device is indicated to record a patient's Withings index during sleep as an aid for diagnosis of OSA. The Withings Sleep Rx is also indicated to record heart rate and movement in an automatic, contactless manner. The device is designed for use in the home screening of adults with suspected sleep breathing disorders. Results are used to assist the healthcare professional in determining the need for further diagnosis and evaluation.	K231667	MNR	2024
AcuPebble Ox200	Acurable Limited	AcuPebble Ox200 is a wearable device intended for use in the recording, analysis, displaying, exporting, and storage of biophysical parameters to aid in the evaluation of adult patients with, or with suspected, OSA. The device is primarily intended for home setting use (although can also be used in healthcare settings) under the direction of a healthcare professional.	K243092	MNR	2025
TipTraQ (TTQ001)	PranaQ Pte. Ltd	The TipTraQ is a wearable device intended for aiding in sleep apnea evaluation/diagnosis for adult patients suspected of sleep apnea in both home-based and clinical-use environments.	K243268	MNR	2025
SANSA HSAT	Huxley Medical	The Huxley Home Sleep Apnea Test (SANSA) is a wearable device intended for use in the recording, analysis, and storage of biophysical parameters to aid in the evaluation of sleep-related breathing disorders of adults suspected of sleep apnea. The device is intended for the clinical and home use setting under the direction of a healthcare professional.	K244027	MNR	2025
<i>Treatment</i>					
Provent	Ventus Medical	Nasal expiratory resistance valve.	K102404	OHP	2010
Winx™	Apnicure, Inc	Nasal expiratory resistance valve.	K122130	OZR	2012
mRNA Appliance	BioModeling Solutions	Expandable oral appliance for the treatment of snoring and mild-to-moderate OSA	K130067	LRK	2014
NightBalance Lunoa System	Philips	The positional sleep trainer is worn with an elasticized chest strap, and is intended to keep patients with positional obstructive sleep apnea from sleeping in the supine position.	K180608	MYB	2018
eXciteOSA	Signifier Medical Technologies	The device delivers neuromuscular stimulation during the day to strengthen the tongue in order to reduce snoring and mild sleep apnea. It is used for 20 minutes once a day for a period of 6 weeks, and once a week thereafter.	K223446	QNO	2021
Respire Clear	Respire Medical, LLC	The device is an oral appliance used in the treatment of mild to moderate OSA. It helps move a patient's jaw forward, thus opening their airways, and allowing them to breathe more easily throughout the night.	K214096	LRK; LQZ	2022

CARE (Complete Airway Repositioning and/or Expansion)	Vivos Therapeutics, Inc	The device is intended to reduce nighttime snoring and to treat mild and moderate obstructive sleep apnea in adults, 18 years of age and older. The device is also intended to treat moderate and severe obstructive sleep apnea in adults, 18 years of age and older along with positive airway pressure devices and/or myofunctional therapy, as needed.	K230947	LRK; LQZ	2023
airVata™	Gelb Practice Solutions, Inc.	The device is intended to reduce nighttime snoring and to treat mild, moderate, and severe OSA in adults age 18 years and older. The device is worn while sleeping to support the lower jaw in a forward position prescribed by the dentist. The appliance is removable by the patient.	K240427	LRK; LQZ	2024
EMA 3D	EMA Sleep Inc.	The EMA 3D is a removable medical device that is fitted in the patient's mouth and is intended to reduce or alleviate snoring and mild to moderate OSA in adults.	K232735	LRK; LQZ	2024
DNA Appliance	Vivos Therapeutics	The device is intended to reduce nighttime snoring and to treat moderate and severe OSA in children 6-17 years of age who are diagnosed with snoring and/or moderate or severe OSA and need orthodontic treatment.	K234089	LRK; LQZ	2024
Rest Assure System	Somnomed, Inc	The device is intended to be used in the treatment of snoring and mild to moderate OSA in patients over 18. Rest Assure has the capability to record and monitor patient compliance to oral device/appliance therapy.	K233497	LRK; LQZ	2024

FDA: Food and Drug Administration; OSA: obstructive sleep apnea

RATIONALE

Summary Of Evidence

For individuals who have obstructive sleep apnea (OSA) who receive positive airway pressure (PAP) devices, the evidence includes randomized controlled trials (RCTs), systematic reviews of RCTs, and a cohort study. Relevant outcomes are symptoms, functional outcomes, and quality of life (QOL). Conventional medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of continuous PAP (CPAP) during sleep. A diagnostic sleep study may be followed by a trial of APAP to evaluate the efficacy and adjust pressure. Studies have suggested that both CPAP and APAP are associated with improvements in sleep architecture. Additionally, 11-year follow-up of obese patients with severe OSA from the Sleep Heart Health Study found a reduction in all-cause mortality with PAP use which appeared after 6 to 7 years. If the patient is intolerant of CPAP, APAP or bilevel PAP may also be indicated. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have OSA who use oral appliances, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, and QOL. Conventional medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of CPAP during sleep. Oral appliances are an accepted therapy for mild-to-moderate OSA. A 2015 and 2022 meta-analysis demonstrated the efficacy of oral appliances for measures of OSA, but they were generally less effective than CPAP. Conflicting data exists on if custom-made oral devices demonstrate superior impact on symptoms and QOL outcomes compared to ready-made oral devices, based on available RCTs. Oral appliances may be an appropriate alternative in patients who refuse or cannot tolerate PAP devices. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have OSA who use neuromuscular electrical tongue stimulation, the evidence includes 1 RCT and 5 prospective single-arm studies (3 with overlapping patient populations). Relevant outcomes are symptoms, functional outcomes, and QOL. The RCT found high adherence to the eXciteOSA device treatment protocol, and exploratory analyses showed improvements in respiratory event index [REI], apnea index, and hypopnea index relative to a sham control but no significant changes in Epworth Sleepiness Scale (ESS) scores. The study was limited by sample size and short follow-up period. The single-arm studies suggest that eXciteOSA may reduce snoring intensity and improve sleep quality, but improvements on the Apnea-Hypopnea Index (AHI) were mixed. Studies were limited to evaluations after the 6-week course of therapy or 2 weeks post-intervention. Larger, well-designed, controlled studies are needed to evaluate improvement in patients who meet the criteria for treatable OSA, to assess continued use after the 6-week trial period, and the durability of observed benefits. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have OSA who receive novel OSA treatments (eg, palate expansion, expiratory positive airway pressure [EPAP], oral pressure therapy, supine vibration), the evidence includes RCTs, prospective single-arm studies, and a meta-analysis of case series. Relevant outcomes are symptoms, functional outcomes, and QOL. The evidence on palate and mandible expansion devices includes a few small series. Further study with well-designed trials is needed to evaluate this treatment. The evidence on nasal EPAP devices in patients with OSA has been reported in prospective case series, an industry-sponsored RCT, smaller RCTs, and a systematic review that did not include the industry-sponsored RCT. The main finding of the industry-sponsored RCT was a decrease in the apnea/hypopnea index (AHI), with a minor impact on oxygenation, and a decrease in ESS. One small RCT with 22 patients found no benefit of an oral EPAP therapy device when added to an oral appliance. One nonrandomized comparative trial with historical controls and a retrospective chart review evaluated a daytime sleep procedure (PAP-NAP) to reduce resistance to CPAP titration or use. Additional study is needed to evaluate the efficacy of this intervention. Several RCTs, observational studies, and a meta-analysis have been published with a sleep positioning device that vibrates when the individual is in a supine position. Drop-out rates were high and long-term compliance is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines And Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy Of Otolaryngology-Head And Neck Surgery

In 2021, the American Academy of Otolaryngology-Head and Neck Surgery updated its position statement on the treatment of obstructive sleep apnea (OSA).⁴⁸ The academy states that adenotonsillectomy is the first line treatment in pediatric OSA. In most adults, continuous positive airway pressure (CPAP) is the first-line treatment. Surgical procedures may be considered when positive airway pressure (PAP) therapy is inadequate.

American Academy Of Pediatrics

The American Academy of Pediatrics (AAP; 2012) published guidelines on the diagnosis and management of uncomplicated childhood OSA associated with adenotonsillar hypertrophy and/or obesity in an otherwise healthy child treated in the primary care setting, which updated the AAP's 2002 guidelines.^{49,50} Adenotonsillectomy was recommended as the first-line treatment for patients with adenotonsillar hypertrophy, and patients should be reassessed clinically postoperatively to determine whether additional treatment is required. High-risk patients should be reevaluated with an objective test or referred to a sleep specialist. CPAP was recommended if adenotonsillectomy was not performed or if OSA persisted postoperatively. Weight loss was recommended in addition to other therapy in patients who are overweight or obese, and intranasal corticosteroids are an option for children with mild OSA in whom adenotonsillectomy is contraindicated or for mild postoperative OSA.

American Academy Of Sleep Medicine

The American Academy of Sleep Medicine (AASM) also issued guidelines in 2009 on the evaluation, management, and long-term care of adults with OSA.⁵¹ The levels of recommendation are "standard" (generally accepted patient-care strategy, with a high degree of certainty; level 1 to 2 evidence), "guideline" (moderate degree of clinical certainty; level 2 to 3 evidence), or "option" (uncertain clinical use; insufficient or inconclusive evidence).

Treatment with PAP:

- CPAP is indicated for patients with moderate to severe OSA (Standard) and mild OSA (Option).
- Bilevel PAP can be considered in CPAP-intolerant patients (Consensus).
- Autotitrating positive airway pressure (APAP) can be considered in CPAP-intolerant patients (Consensus).

Treatment with oral appliances (OA) is indicated for "patients with mild to moderate OSA, who prefer OAs to CPAP, or who do not respond to CPAP, or are not appropriate candidates for CPAP, or who fail CPAP ... (Guideline)."

- Mandibular repositioning appliance covers the upper and lower teeth.
- Tongue-retaining device holds the tongue in a forward position.

The AASM (2019) also published a clinical practice guideline on the treatment of OSA with PAP that was based on a systematic review of the evidence.⁵² "A STRONG (ie, "We recommend...") recommendation is one that clinicians should follow under most circumstances. A CONDITIONAL recommendation (ie, "We suggest...") reflects a lower degree of certainty regarding the outcome and appropriateness of the patient-care strategy for all patients."

The AASM provided strong recommendations for the following use of PAP therapy in adults:

- Use of PAP to treat OSA in adults with excessive sleepiness.
- That PAP therapy be initiated at home using APAP or in-laboratory PAP titration in adults with no significant morbidities.
- Use of CPAP or APAP for ongoing treatment of OSA.
- That clinicians provide educational interventions with the initiation of PAP.

The AASM provided conditional recommendations (suggest) for the following use of PAP therapy in adults:

- Use of PAP to treat OSA in adults with impaired sleep-related quality of life (QOL).
- Use of PAP to treat OSA in adults with comorbid hypertension.
- Use CPAP or APAP over Bilevel PAP in the routine treatment of OSA.
- That behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy.
- That clinicians use telemonitoring during the initial period of PAP therapy.

The AASM and the American Academy of Dental Sleep Medicine (2015) published guidelines on the treatment of OSA and snoring with OA therapy.²⁰ The 2 societies provided a recommendation of "standard" that sleep physicians consider prescription of OA, rather than no treatment, for adults with OSA who are intolerant

of CPAP therapy or prefer alternative therapy. The quality of evidence was rated as moderate. "Guideline" recommendations were provided for the use of custom, titratable appliance over noncustom oral devices, that qualified dentists provide oversight, that sleep physicians conduct follow-up sleep testing to improve or confirm treatment efficacy, and that patients return for periodic office visits with a qualified dentist and a sleep physician.

In 2025, the AASM issued a statement following Food and Drug Administration (FDA) approval of Zepbound for adults with moderate-to-severe OSA and obesity.⁵³ The AASM recommends that treatment with Zepbound be evaluated by an accredited sleep center and highlights its role as an adjunctive option, particularly for patients whose OSA is primarily obesity-driven. The statement says that Zepbound is not universally effective and should be considered alongside established therapies—such as PAP, oral appliances, or upper airway stimulation—especially when anatomical factors contribute to OSA, and clinicians should counsel patients on the importance of sustained weight loss and potential adverse effects.

American Heart Association

In 2021, the American Heart Association (AHA) published a scientific statement on OSA and cardiovascular disease.⁵⁴ The treatment options for OSA and eligibility for their use are described in the statement and briefly summarized below:

- CPAP: "The Centers for Medicare & Medicaid Services [CMS] cover CPAP on the basis of an AHI [apnea/hypopnea index] or REI [respiratory event index] ≥ 15 events per hour or AHI (or REI) ≥ 5 with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented comorbidities (ie, hypertension, ischemic heart disease, or history of stroke)."
- APAP: "Same as CPAP."
- Bilevel PAP: "Patients intolerant of CPAP pressure or who require additional ventilatory support."
- Positional therapy: "Indicated for positional sleep apnea defined by breathing events only (isolated) or predominantly in the supine posture often considered as supine AHI at least double the lateral AHI."
- Oral appliances: "Alternative to CPAP for mild to moderate OSA or in patients who do not tolerate CPAP."

The statement also notes the following with regards to treatment:

"All patients with OSA should be considered for treatment, including behavioral modifications and weight loss as indicated. Continuous positive airway pressure should be offered to patients with severe OSA, whereas oral appliances can be considered for those with mild to moderate OSA or for continuous positive airway pressure-intolerant patients. Follow-up sleep testing should be performed to assess the effectiveness of treatment."

American Society Of Metabolic And Bariatric Surgery

The American Society of Metabolic and Bariatric Surgery (2012) published guidelines on the perioperative management of OSA (reviewed in October 2015).⁵⁵ The guidelines noted that while some reports in the literature have recommended routine screening for OSA prior to bariatric surgery, other reports have suggested clinical screening only does not result in any increase in postoperative pulmonary complications after laparoscopic Roux-en-Y gastric bypass, and that most current surgical practices refer patients with clinical symptoms of OSA for polysomnography (PSG), but do not make this a routine preoperative test prior to bariatric surgery. The Society provided, based on the evidence in the literature to date, the following guidelines on OSA in the bariatric surgery patient and its perioperative management:

1. "OSA is highly prevalent in the bariatric patient population...."
4. [Patients with moderate to severe OSA] should bring their CPAP machines, or at least their masks, with them at the time of surgery and use them following bariatric surgery at the discretion of the surgeon.
7. Routine pulse oximetry or capnography for postoperative monitoring of patients with OSA after bariatric surgery should be utilized, but the majority of these patients do not routinely require an ICU [intensive care unit] setting.
8. No clear guidelines exist upon which to base recommendations for retesting for OSA following bariatric surgery...."

American Thoracic Society

The American Thoracic Society (2016) published a research statement on the long-term effects and treatment of mild OSA in adults.⁵⁶ The Society's systematic review concluded:

- Daytime sleepiness: subjective improvement with CPAP; unclear effect of non-CPAP therapies
- QOL: small improvements seen in different domains in different studies
- Neurocognition: treatment effects inconsistent.

National Institute For Health And Care Excellence

NICE provides guidance on medical management in individuals with varying degrees of OSA.⁵⁷ They recommend offering fixed-level CPAP in those with mild OSA when symptoms affect QOL and usual daytime activities if lifestyle changes alone have been unsuccessful or are considered inappropriate. They recommend APAP as an alternative to fixed-level CPAP in those unable to tolerate CPAP. In individuals who cannot tolerate or refuse CPAP, they recommend offering a customized mandibular advancement device. In individuals with moderate to severe OSA, CPAP is recommended as a treatment option, with APAP offered as an alternative in those unable to tolerate CPAP. Similarly, a customized mandibular advancement device may be used if an individual refuses PAP or is unable to tolerate PAP. NICE also states that a positional modifier may be considered for those with mild to moderate positional OSA if other treatments are unsuitable or not tolerated, but this should not be a first-line treatment option.

NICE published guidance on daytime intraoral neuromuscular electrical tongue stimulation for obstructive sleep apnea in 2023.⁵⁸ A rapid review of evidence identified 1 single-arm trial and 1 pilot study and also considered 2 submissions from patient organizations about the procedure. NICE recommended that the procedure should only be used in a research setting due to an inadequate quantity and quality of evidence and that further adequately powered randomized controlled trials (RCTs) and analysis of observational data should be used to assess efficacy, safety, and adherence.

VA/DOD Clinical Practice Guidelines

The Department of Veterans Affairs (VA) and the Department of Defense (DOD) published a research statement on the management of chronic insomnia disorder and OSA (2025).⁵⁹

For treatment of OSA, we recommend one or more of the following evidence-based therapies, depending on patient values and characteristics (Strong level of evidence for, Newly added):

- Mandibular advancement devices
- PAP
- Referral for surgical evaluation

For treatment of mild to moderate OSA (Event Index <30 per hour), we suggest either mandibular advancement devices or PAP as first-line therapy options (Weak level of evidence for, Amended).

For the treatment of positional OSA, we suggest positional therapy (Weak, Newly added).

U.S. Preventive Services Task Force Recommendations

None.

Medicare National Coverage

In 2001, CMS published a decision memorandum on CPAP that addressed how to define moderate-to-severe OSA as a guide to a coverage policy for CPAP. This review of the literature suggested there is a risk of hypertension with an AHI greater than 15 events per hour, and thus treatment would be warranted for these patients without any additional signs and symptoms. For patients with an AHI between 5 and 15 events per hour and associated symptoms, CMS concluded that the data from 3 randomized controlled trials demonstrated improved daytime somnolence and functioning in those treated with CPAP.

In 2008, CMS expanded coverage of CPAP to include those beneficiaries with a diagnosis of OSA made with a combination of clinical evaluation and unattended home sleep monitoring using a device with at least 3 channels.^{60,61} There is variability in the published medical literature about the definition of the events that constitute a respiratory disturbance, and, for the purposes of this national coverage decision, a respiratory disturbance was defined in the context of the sleep test technology of interest and, for portable monitoring devices that do not measure AHI or Respiratory Disturbance Index (RDI) directly, does not require direct measurement of airflow.

Effective in March 2008, CMS determined that CPAP therapy, when used in adults with OSA, would be considered reasonable and necessary in the following situations:

1. "The use of CPAP is covered under Medicare when used in adult patients with OSA. Coverage of CPAP is initially limited to a 12-week period to identify beneficiaries diagnosed with OSA as subsequently described who benefit from CPAP. CPAP is subsequently covered only for those beneficiaries diagnosed with OSA who benefit from CPAP during this 12-week period.
2. The provider of CPAP must conduct education of the beneficiary prior to the use of the CPAP device to ensure that the beneficiary has been educated in the proper use of the device. A caregiver, for example, a family member, may be compensatory, if consistently available in the beneficiary's home and willing and able to safely operate the CPAP device.
3. A positive diagnosis of OSA for the coverage of CPAP must include clinical evaluation and a positive:
 - a. attended PSG performed in a sleep laboratory; or
 - b. unattended HST [home sleep test] with a Type II home sleep monitoring device; or
 - c. unattended HST with a Type III home sleep monitoring device; or
 - d. unattended HST with a Type IV home sleep monitoring device that measures at least 3 channels.
4. The sleep test must have been previously ordered by the beneficiary's treating physician and furnished under appropriate physician supervision.
5. An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criteria using the AHI or RDI are met:
 - a. AHI or RDI greater than or equal to 15 events per hour, or
 - b. AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.
6. The AHI or RDI is calculated on the average number of events of per hour. If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at minimum the number of events that would have been required in a 2-hour period.
7. Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline and with at least a 4% oxygen desaturation.
8. Coverage with Evidence Development (CED): Medicare provides the following limited coverage for CPAP in adult beneficiaries who do not qualify for CPAP coverage based on criteria 1-7 above. A clinical study seeking Medicare payment for CPAP provided to a beneficiary who is an enrolled subject in that study must address 1 or more of the following questions:
 - a. In Medicare aged subjects with clinically identified risk factors for OSA, how does the diagnostic accuracy of a clinical trial of CPAP compare with PSG and Types II, III & IV HST in identifying subjects with OSA who will respond to CPAP?

Ongoing And Unpublished Clinical Trials

A search of [ClinicalTrials.gov](#) in May 2026 identified over 200 ongoing studies on the medical management of OSA.

CODES		
Codes	Number	Description
ICD10 CM	G47.33	Obstructive sleep apnea (adult) pediatric
	R06.81	Apnea, not elsewhere classified
	R40.0	Somnolence
	G47.30	Sleep apnea, unspecified
	G47.8	Other sleep disorders
	G47.9	Sleep disorder unspecified

CURRENT CODING

CPT:

Code	Description	Line of Business
0964T	Impression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; single arch, without mandibular advancement mechanism	FEP
0965T	Impression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, non-fixed hinge mechanism	FEP
0966T	Impression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, fixed hinge mechanism	FEP

HCPCS:

Code	Description	Line of Business
A7027	Combination oral/nasal mask, used with continuous positive airway pressure device, each	FEP
A7028	Oral cushion for combination oral/nasal mask, replacement only, each	FEP
A7029	Nasal pillows for combination oral/nasal mask, replacement only, pair	FEP
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	FEP
A7035	Headgear used with positive airway pressure device	FEP

Code	Description	Line of Business
A7036	Chinstrap used with positive airway pressure device	FEP
A7037	Tubing used with positive airway pressure device	FEP
A7038	Filter, disposable, used with positive airway pressure device	FEP
A7039	Filter, non disposable, used with positive airway pressure device	FEP
A7049	Expiratory positive airway pressure intranasal resistance valve	FEP
E0470	Respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)	FEP
E0471	Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)	FEP
E0485	Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, prefabricated, includes fitting and adjustment	FEP
E0486	Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment	FEP
E0490	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote	FEP
E0491	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply	FEP
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application	FEP
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	FEP
E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	FEP
E0561	Humidifier, non-heated, used with positive airway pressure device	FEP
E0562	Humidifier, heated, used with positive airway pressure device	FEP
E0601	Continuous positive airway pressure (cpap) device	FEP
K1027	Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment	FEP

REFERENCES

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. Sep 02 2008; 118(10): 1080-111. PMID 18725495
2. Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. Apr 2005; 28(4): 499-521. PMID 16171294
3. Crook S, Sievi NA, Bloch KE, et al. Minimum important difference of the Epworth Sleepiness Scale in obstructive sleep apnoea: estimation from three randomised controlled trials. Thorax. Apr 2019; 74(4): 390-396. PMID 30100576

4. Patil SP, Ayappa IA, Caples SM, et al. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med*. Feb 15 2019; 15(2): 301-334. PMID 30736888
5. Balk EM, Moorthy D, Obadan NO, et al. Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. Comparative Effectiveness Review No. 32 (AHRQ Publication No. 11-EHC052-EF). Rockville, MD: Agency for Healthcare Research and Quality; 2011.
6. Berry RB, Parish JM, Hartse KM. The use of auto-titrating continuous positive airway pressure for treatment of adult obstructive sleep apnea. *An American Academy of Sleep Medicine review. Sleep*. Mar 15 2002; 25(2): 148-73. PMID 11902425
7. Littner M, Hirshkowitz M, Davila D, et al. Practice parameters for the use of auto-titrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome. *An American Academy of Sleep Medicine report. Sleep*. Mar 15 2002; 25(2): 143-7. PMID 11902424
8. Kushida CA, Morgenthaler TI, Littner MR, et al. Practice parameters for the treatment of snoring and Obstructive Sleep Apnea with oral appliances: an update for 2005. *Sleep*. Feb 2006; 29(2): 240-3. PMID 16494092
9. Morgenthaler TI, Aurora RN, Brown T, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. *An American Academy of Sleep Medicine report. Sleep*. Jan 2008; 31(1): 141-7. PMID 18220088
10. Hussain SF, Love L, Burt H, et al. A randomized trial of auto-titrating CPAP and fixed CPAP in the treatment of obstructive sleep apnea-hypopnea. *Respir Med*. Apr 2004; 98(4): 330-3. PMID 15072173
11. Marrone O, Resta O, Salvaggio A, et al. Preference for fixed or automatic CPAP in patients with obstructive sleep apnea syndrome. *Sleep Med*. May 2004; 5(3): 247-51. PMID 15165530
12. Stammnitz A, Jerrentrup A, Penzel T, et al. Automatic CPAP titration with different self-setting devices in patients with obstructive sleep apnoea. *Eur Respir J*. Aug 2004; 24(2): 273-8. PMID 15332397
13. Yu J, Zhou Z, McEvoy RD, et al. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. *JAMA*. Jul 11 2017; 318(2): 156-166. PMID 28697252
14. McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med*. Sep 08 2016; 375(10): 919-31. PMID 27571048
15. Lisan Q, Van Sloten T, Marques Vidal P, et al. Association of Positive Airway Pressure Prescription With Mortality in Patients With Obesity and Severe Obstructive Sleep Apnea: The Sleep Heart Health Study. *JAMA Otolaryngol Head Neck Surg*. Jun 01 2019; 145(6): 509-515. PMID 30973594
16. Benjafield AV, Pepin JL, Cistulli PA, et al. Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies. *Lancet Respir Med*. May 2025; 13(5): 403-413. PMID 40118084
17. Fox N, Hirsch-Allen AJ, Goodfellow E, et al. The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: a randomized controlled trial. *Sleep*. Apr 01 2012; 35(4): 477-81. PMID 22467985
18. Mutter TC, Chateau D, Moffatt M, et al. A matched cohort study of postoperative outcomes in obstructive sleep apnea: could preoperative diagnosis and treatment prevent complications?. *Anesthesiology*. Oct 2014; 121(4): 707-18. PMID 25247853
19. Pattipati M, Gudavalli G, Zin M, et al. Continuous Positive Airway Pressure vs Mandibular Advancement Devices in the Treatment of Obstructive Sleep Apnea: An Updated Systematic Review and Meta-Analysis. *Cureus*. Jan 2022; 14(1): e21759. PMID 35251830
20. Ramar K, Dort LC, Katz SG, et al. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. *J Clin Sleep Med*. Jul 15 2015; 11(7): 773-827. PMID 26094920
21. Yu M, Ma Y, Han F, et al. Long-term efficacy of mandibular advancement devices in the treatment of adult obstructive sleep apnea: A systematic review and meta-analysis. *PLoS One*. 2023; 18(11): e0292832. PMID 38015938
22. Liao J, Shi Y, Gao X, et al. Efficacy of Oral Appliance for Mild, Moderate, and Severe Obstructive Sleep Apnea: A Meta-analysis. *Otolaryngol Head Neck Surg*. May 2024; 170(5): 1270-1279. PMID 38363016
23. Johal A, Haria P, Manek S, et al. Ready-Made Versus Custom-Made Mandibular Repositioning Devices in Sleep Apnea: A Randomized Clinical Trial. *J Clin Sleep Med*. Feb 15 2017; 13(2): 175-182. PMID 27784410
24. Bosschieter PFN, Uniken Venema JAM, Vonk PE, et al. Equal effect of a noncustom vs a custom mandibular advancement device in treatment of obstructive sleep apnea. *J Clin Sleep Med*. Sep 01 2022; 18(9): 2155-2165. PMID 35532113
25. Belkhorde V, Godbole S, Nimonkar S, et al. Comparative evaluation of the efficacy of customized maxillary oral appliance with mandibular advancement appliance as a treatment modality for moderate obstructive sleep apnea patients-a randomized controlled trial. *Trials*. Feb 01 2023; 24(1): 73. PMID 36726182
26. Abreu AR, Stefanovski D, Patil SP, et al. Neuromuscular electrical stimulation for obstructive sleep apnoea: comparing adherence to active and sham therapy. *ERJ Open Res*. Nov 2023; 9(6). PMID 38152084
27. Wessollock E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. *Somnologie (Berl)*. 2018; 22(Suppl 2): 47-52. PMID 30595662
28. Kotecha B, Wong PY, Zhang H, et al. A novel intraoral neuromuscular stimulation device for treating sleep-disordered breathing. *Sleep Breath*. Dec 2021; 25(4): 2083-2090. PMID 33772397
29. Baptista PM, Martínez Ruiz de Apodaca P, Carrasco M, et al. Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring in Individuals with Primary Snoring and Mild Obstructive Sleep Apnea. *J Clin Med*. Apr 27 2021; 10(9). PMID 33925376
30. Nokes B, Schmickl CN, Brena R, et al. The impact of daytime transoral neuromuscular stimulation on upper airway physiology - A mechanistic clinical investigation. *Physiol Rep*. Jun 2022; 10(12): e15360. PMID 35748091
31. Nokes B, Baptista PM, de Apodaca PMR, et al. Transoral awake state neuromuscular electrical stimulation therapy for mild obstructive sleep apnea. *Sleep Breath*. May 2023; 27(2): 527-534. PMID 35624401
32. Singh GD, Griffin T, Cress SE. Biomimetic oral appliance therapy in adults with severe obstructive sleep apnea. *J Sleep Disord Ther*. 2016;5:227.
33. Singh GD, Cress SE. Biomimetic oral appliance therapy in adults with mild to moderate obstructive sleep apnea using combined maxillo-mandibular correction. *J Sleep Disord Manag*. 2017;3(1):014.
34. Krakow B, Ulibarri V, Melendrez D, et al. A daytime, abbreviated cardio-respiratory sleep study (CPT 95807-52) to acclimate insomnia patients with sleep disordered breathing to positive airway pressure (PAP-NAP). *J Clin Sleep Med*. Jun 15 2008; 4(3): 212-22. PMID 18595433
35. Ulibarri VA, Krakow B, McIver ND. The PAP-NAP one decade later: patient risk factors, indications, and clinically relevant emotional and motivational influences on PAP use. *Sleep Breath*. Dec 2020; 24(4): 1427-1440. PMID 31898192
36. Riaz M, Certal V, Nigam G, et al. Nasal Expiratory Positive Airway Pressure Devices (Provent) for OSA: A Systematic Review and Meta-Analysis. *Sleep Disord*. 2015; 2015: 734798. PMID 26798519

37. Berry RB, Kryger MH, Massie CA. A novel nasal expiratory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: a randomized controlled trial. *Sleep*. Apr 01 2011; 34(4): 479-85. PMID 21461326
38. Kryger MH, Berry RB, Massie CA. Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA). *J Clin Sleep Med*. Oct 15 2011; 7(5): 449-53B. PMID 22003339
39. Kureshi SA, Gallagher PR, McDonough JM, et al. Pilot study of nasal expiratory positive airway pressure devices for the treatment of childhood obstructive sleep apnea syndrome. *J Clin Sleep Med*. Jun 15 2014; 10(6): 663-9. PMID 24932147
40. Lai V, Tong BK, Tran C, et al. Combination therapy with mandibular advancement and expiratory positive airway pressure valves reduces obstructive sleep apnea severity. *Sleep*. Aug 01 2019; 42(8). PMID 31180512
41. Srijithesh PR, Aghoram R, Goel A, et al. Positional therapy for obstructive sleep apnoea. *Cochrane Database Syst Rev*. May 01 2019; 5(5): CD010990. PMID 31041813
42. Eijsvogel MM, Ubbink R, Dekker J, et al. Sleep position trainer versus tennis ball technique in positional obstructive sleep apnea syndrome. *J Clin Sleep Med*. Jan 15 2015; 11(2): 139-47. PMID 25515276
43. de Ruiter MHT, Benoist LBL, de Vries N, et al. Durability of treatment effects of the Sleep Position Trainer versus oral appliance therapy in positional OSA: 12-month follow-up of a randomized controlled trial. *Sleep Breath*. May 2018; 22(2): 441-450. PMID 28913630
44. Berry RB, Uhles ML, Abaluck BK, et al. NightBalance Sleep Position Treatment Device Versus Auto-Adjusting Positive Airway Pressure for Treatment of Positional Obstructive Sleep Apnea. *J Clin Sleep Med*. Jul 15 2019; 15(7): 947-956. PMID 31383231
45. van Maanen JP, de Vries N. Long-term effectiveness and compliance of positional therapy with the sleep position trainer in the treatment of positional obstructive sleep apnea syndrome. *Sleep*. Jul 01 2014; 37(7): 1209-15. PMID 25061249
46. Beyers J, Dieltjens M, Kastoer C, et al. Evaluation of a Trial Period With a Sleep Position Trainer in Patients With Positional Sleep Apnea. *J Clin Sleep Med*. Apr 15 2018; 14(4): 575-583. PMID 29609712
47. Buyse B, Ciordas S, Hoet F, et al. Positional obstructive sleep apnoea: challenging findings in consecutive patients treated with a vibrating position trainer. *Acta Clin Belg*. Dec 2019; 74(6): 405-413. PMID 30433857
48. American Academy of Otolaryngology-Head and Neck Surgery. Position Statement: Treatment of obstructive sleep apnea. 2021 <https://www.entnet.org/resource/position-statement-treatment-of-obstructive-sleep-apnea/> Accessed May 6, 2026.
49. Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome. American Academy of Pediatrics. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. Apr 2002; 109(4): 704-12. PMID 11927718
50. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. Sep 2012; 130(3): 576-84. PMID 22926173
51. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. Jun 15 2009; 5(3): 263-76. PMID 19960649
52. Patil SP, Ayappa IA, Caples SM, et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. Feb 15 2019; 15(2): 335-343. PMID 30736887
53. American Academy of Sleep Medicine (AASM). AASM statement on Zepbound approval. Dec 23, 2024. <https://aasm.org/zepbound-approval-sleep-apnea-american-academy-sleep-medicine-statement>. Accessed May 6, 2026.
54. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. Jul 20 2021; 144(3): e56-e67. PMID 34148375
55. ASMBs Clinical Issues Committee. Peri-operative management of obstructive sleep apnea. *Surg Obes Relat Dis*. 2012; 8(3): e27-32. PMID 22503595
56. Chowdhuri S, Quan SF, Almeida F, et al. An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep Apnea in Adults. *Am J Respir Crit Care Med*. May 01 2016; 193(9): e37-54. PMID 27128710
57. National Institute for Health and Care Excellence (NICE). Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: NG202. Published August 20, 2021; <https://www.nice.org.uk/guidance/ng202/chapter/1-Obstructive-sleep-apnoeahypopnoea-syndrome#treatments-for-mild-osahs>. Accessed May 5, 2026.
58. National Institute for Health and Care Excellence (NICE). Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea [HTG672]. April 19, 2023. <https://www.nice.org.uk/guidance/htg672>. Accessed May 6, 2026.
59. The Department of Veteran's Affairs and the Department of Defense (VA/DOD). VA/DOD Clinical Practice Guideline For The Management Of Chronic Insomnia Disorder And Obstructive Sleep Apnea. January, 2025. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>. Accessed May 6, 2026.
60. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Continuous Positive Airway Pressure (CPAP) Therapy For Obstructive Sleep Apnea (OSA) (240.4). 2008; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226&ver=3>. Accessed May 5, 2026.
61. Centers for Medicare & Medicaid Services (CMS). CMS Manual System: Pub 100-03 Medicare National Coverage Determinations. Transmittal 96. Change request 6048. 2008; <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r96ncd.pdf>. Accessed May 6, 2026.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2022	New policy	Policy created with literature review through April 16, 2022. Relevant information was moved from 2.01.18 (Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome); references added. Policy statements unchanged.
September 2023	Replace policy	Policy updated with literature review through May 9, 2023; references added. Policy statements unchanged.

Date	Action	Description
September 2024	Replace policy	Policy updated with literature review through May 6, 2024; references added. Additional indication added for neuromuscular electrical tongue stimulation with a new policy statement: The use of neuromuscular electrical tongue stimulation is considered investigational for the treatment of OSA. Other policy statements are unchanged.
September 2025	Replace policy	Policy updated with literature review through April 4, 2025; references added. Policy statements unchanged.
March 2026	Replace policy	Policy updated with literature review through April 4, 2025; references added. Policy statements unchanged.
July 2026	Replace policy	Removed (eff 7/1/2025) for codes 0964T, 0965T, 0966T.
September 2026	Replace policy	Policy updated with literature review through May 6, 2026; reference added. Policy statements edited for clarity and consistency. Intent unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Plans that elect to use the BCBSA reference medical policies as their Plan medical policies should ensure that all internal and external communications clearly reflect that it is the Plan, and not BCBSA, that makes the Plan's policy decisions, and the Plan must place the contents of the reference medical policy on their respective Plan medical policy template. When a Plan elects to adopt any or all of the reference medical policies, the Plan makes an independent decision regarding medical policies and is fully responsible for that decision.